Abstract

For the past few years adipokines have been a center of appreciation and interest. They are biologically active molecules causing pleiotropic effects. They assist in angiogenesis, adipose tissue metabolism and inflammation, and modulate tissue sensitivity for insulin. Adipokines are produced in adipose tissue, so an abnormal quantity of this tissue leads to impaired levels of these factors. Because of their different concentrations in various conditions, it would be plausible to use them as markers for individual conditions, such as obesity, type 2 diabetes mellitus, pancreatitis, gastric cancer, lung cancer or colon cancer. Such adipokines as leptin, resistin, visfatin, adiponectin, and apelin are subjects of research. In our study we focused on the function and significance of chemerin and omentin in metabolic syndrome and cancers. In type 2 diabetes mellitus, both chemerin and omentin enhance the body sensitivity to insulin, which results in increased glucose uptake. However, in diabetic patients, serum concentration of omentin decreases, while that of chemerin increases. A similar trend was observed in obese patients. As a cancer marker, chemerin turned out to be helpful in diagnosis of gastric cancer, mesothelioma, and polycystic ovary syndrome, which can lead to endometrial cancer. An elevated concentration of omentin was noted in colon cancer, and increased expression of the omentin gene was reported in nasal polyps and mesothelioma.

References

• 1. Aktas G., Alcelik A., Ozlu T., Tosun M., Tekce B.K., Savli H., Tekce A.,Dikbas O.: Association between omentin levels and insulin resistancein pregnancy. Exp. Clin. Endocrinol. Diabetes, 2014; 122: 163-166
  Google Scholar
• 2. Bozaoglu K., Bolton K., McMillan J., Zimmet P., Jowett J., CollierG., Walder K., Segal D.: Chemerin is a novel adipokine associatedwith obesity and metabolic syndrome. Endocrinology, 2007; 148:4687-4694
  Google Scholar
• 3. Bozaoglu K., Curran J.E., Stocker C.J., Zaibi M.S., Segal D., KonstantopoulosN., Morrison S., Carless M., Dver T.D., Cole S.A., GoringH.H., Moses E.K., Walder K., Cawthorne M.A., Blangero J. i wsp.:Chemerin, a novel adipokine in the regulation of angiogenesis. J.Clin. Endocrinol. Metab., 2010; 95: 2476-2485
  Google Scholar
• 4. Bozaoglu K., Segal D., Shields K.A., Cummings N., Curran J.E., ComuzzieA.G., Mahaney M.C., Rainwater D.L., WandenBerg J.L., MacCluerJ.W., Collier G., Blangero J., Walser K., Jovett J.B.: Chemerinis associated with metabolic syndrome phenotypes in a MexicanAmericanpopulation. J. Clin. Endocrinol. Metab., 2009; 94: 3085-3088
  Google Scholar
• 5. Brunetti L., Leone S., Orlando G., Ferrante C., Recinella L., ChiavaroliA., Di Nisio C., Shohreh R., Manippa F., Ricciuti A., Vacca M.:Hypotensive effects of omentin-1 related to increased adiponectinand decreased interleukin-6 in intra-thoracic pericardial adiposetissue. Pharmacol. Rep., 2014; 66: 991-995
  Google Scholar
• 6. Chakaroun R., Raschpichler M., Klöting N., Oberbach A., FlehmigG., Kern M., Shön M.R., Shang E., Lohmann T., Dreβler M., FasshauerM., Stumvoll M., Blüher M.: Effects of weight loss and exercise onchemerin serum concentrations and adipose tissue expression inhuman obesity. Metabolism, 2012; 61: 706-714
  Google Scholar
• 7. de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z.,Pray J., Ndubuizu K., Patil S., Schwartz A., Kligman M., Fried SK.,Gong DW., Shuldiner A.R., Pollin T.I., McLenithan J.C.: Omentin plasmalevels and gene expression are decreased in obesity. Diabetes,2007; 56: 1655-1661
  Google Scholar
• 8. Fatima S.S., Bozaoglu K., Rehman R., Alam F., Memon A.S.: Elevatedchemerin levels in Pakistani men: an interrelation with metabolicsyndrome phenotypes. PLoS One, 2013; 8: e57113
  Google Scholar
• 9. Fazeli M.S., Dashti H., Akbarzadeh S., Assadi M., Aminian A., KeramatiM.R., Nabipour I.: Circulating levels of novel adipocytokines inpatients with colorectal cancer. Cytokine, 2013; 62: 81-85
  Google Scholar
• 10. Fernandez-Ranvier G.G., Weng J., Yeh R.F., Khanafshar E., Suh I.,Barker C., Duh Q.Y., Clark O.H., Kebebew E.: Identification of biomarkersof adrenocortical carcinoma using genomewide gene expressionprofiling. Arch. Surg., 2008; 143: 841-846
  Google Scholar
• 11. Goralski K.B., McCarthy T.C., Hanniman E.A., Zabel B.A., ButcherE.C., Parlee S.D., Muruganandan S., Sinal C.J.: Chemerin, a noveladipokine that regulates adipogenesis and adipocyte metabolism.J. Biol. Chem., 2007; 282: 28175-28188
  Google Scholar
• 12. Guzel E.C., Celik C., Abali R., Kucukyalcin V., Celik E., Guzel M.,Yilmaz M.: Omentin and chemerin and their association with obesityin women with polycystic ovary syndrome. Gynecol. Endocrinol.,2014; 30: 419-422
  Google Scholar
• 13. Hah Y.J., Kim N.K., Kim M.K., Kim H.S, Hur S.H., Yoon H.J., KimY.N., Park K.G.: Relationship between chemerin levels and cardiometabolicparameters and degree of coronary stenosis in Koreanpatients with coronary artery disease. Diabetes Metab. J., 2011; 35:248-254
  Google Scholar
• 14. Kataoka Y., Shibata R., Ohashi K., Kambara T., Enomoto T., UemuraY., Oqura Y., Yuasa D., Matsuo K., Nagata T., Oba T., Yasukawa H.,Numaquchi Y., Sone T., Murohara T. i wsp.: Omentin prevents myocardialischemic injury through AMP-activated protein kinase- andAkt-dependent mechanisms. J. Am. Coll. Cardiol., 2014; 63: 2722-2733
  Google Scholar
• 15. Lapointe M., Poirier P., Martin J., Bastien M., Auclair A., CianfloneK.: Omentin changes following bariatric surgery and predictivelinks with biomarkers for risk of cardiovascular disease. Cardiovasc.Diabetol., 2014; 13: 124
  Google Scholar
• 16. Liu R., Wang X., Bu P.: Omentin-1 is associated with carotidatherosclerosis in patients with metabolic syndrome. Diabetes Res.Clin. Pract., 2011; 93: 21-25
  Google Scholar
• 17. Mohr S., Bottin M.C., Lannes B., Neuville A., Bellocq J.P., KeithG., Rihn B.H.: Microdissection, mRNA amplification and microarray:a study of pleural mesothelial and malignant mesothelioma cells.Biochimie, 2004; 86: 13-19
  Google Scholar
• 18. Moreno-Navarrete J.M., Catalán V., Ortega F., Gómez-AmbrosiJ., Ricart W., Frühbeck G., Fernández-Real J.M.: Circulating omentinconcentration increases after weight loss. Nutr. Metab., 2010; 7: 27
  Google Scholar
• 19. Nagpal S., Patel S., Jacobe H., DiSepio D., Ghosn C., Malhotra M.Teng M., Duvic M., Chandraratna R.A.: Tazarotene-induced gene 2(TIG2), a novel retinoid-responsive gene in skin. J. Invest. Dermatol.,1997; 109: 91-95
  Google Scholar
• 20. Niedźwiedzka-Rystwej P., Trzeciak-Ryczek A., Deptuła W.: Tkanka tłuszczowa i jej rola w odporności – nowe dane. Alergia AstmaImmunologia, 2012, 17: 16-21
  Google Scholar
• 21. Onur I., Oz F., Yildiz S., Kuplay H., Yucel C., Sigirci S., Elitok A.,Piten S., Kasali K., Yasar Cizgici A., Erentug V., Dinckal H.M.: A decreasedserum omentin-1 level may be an independent risk factorfor peripheral arterial disease. Int. Angiol., 2014; 33: 455-460
  Google Scholar
• 22. Park I.H., Park S.J., Cho J.S., Moon Y.M., Kim T.H., Lee S.H., LeeH.M.: Increased expression of intelectin-1 in nasal polyps. Am. J.Rhinol. Allergy, 2012; 26: 274-277
  Google Scholar
• 23. Saremi A., Asghari M., Ghorbani A.: Effects of aerobic trainingon serum omentin-1 and cardiometabolic risk factors in overweightand obese men. J. Sports Sci., 2010; 28: 993-998
  Google Scholar
• 24. Sell H., Divoux A., Poitou C., Basdevant A., Bouillot J.L., BedossaP., Tordjman J., Eckel J., Clément K.: Chemerin correlates with markersfor fatty liver in morbidly obese patients and strongly decreasesafter weight loss induced by bariatric surgery. J. Clin. Endocrinol.Metab., 2010; 95: 2892-2896
  Google Scholar
• 25. Stejskal D., Karpisek M., Hanulova Z., Svestak M.: Chemerin isan independent marker of the metabolic syndrome in a Caucasianpopulation – a pilot study. Biomed. Pap. Med. Fac. Univ. Palacky OlomoucCzech Repub., 2008; 152: 217-221
  Google Scholar
• 26. Tan B.K., Adya R., Randeva H.S.: Omentin: a novel link betweeninflammation, diabesity, and cardiovascular disease. Trends Cardiovasc.Med., 2010; 20: 143-148
  Google Scholar
• 27. Uemura Y., Shibata R., Kanemura N., Ohashi K., Kambara T.,Hiramatsu-Ito M., Enomoto T., Yuasa D., Joki Y., Matsuo K., Ito M.,Hayakawa S., Oqawa H., Murohara T., Ouchi N.: Adipose-derived proteinomentin prevents neointimal formation after arterial injury.FASEB J., 2015; 29: 141-151
  Google Scholar
• 28. Uyeturk U., Sarici H., Kin T.B., Eroglu M., Kemahli E., UyeturkU., Gucuk A.: Serum omentin level in patients with prostate cancer.Med. Oncol., 2014; 31: 923
  Google Scholar
• 29. Washimi K., Yokose T., Yamashita M., Kageyama T., Suzuki K.,Yoshihara M., Miyagi Y., Hayashi H., Tsuji S.: Specific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinalgoblet cells. PLoS One, 2012; 7: e39889
  Google Scholar
• 30. Wójcik M., Chmielewska-Kassassir M., Grzywnowicz K., WoźniakL., Cypryk K.: The relationship between adipose tissue-derived hormonesand gestational diabetes mellitus (GDM). Endokrynol. Pol.,2014; 65: 134-142
  Google Scholar
• 31. Wu S.S., Liang Q.H., Liu Y., Cui R.R., Yuan L.Q., Liao E.Y.: Omentin-1stimulates human osteoblast proliferation through PI3K/Aktsignal pathway. Int. J. Endocrinol., 2013; 2013: 368970
  Google Scholar
• 32. Yamawaki H., Tsubaki N., Mukohda M., Okada M., Hara Y.: Omentin,a novel adipokine, induces vasodilation in rat isolated blood vessels.Biochem. Biophys. Res. Commun., 2010; 393: 668-672
  Google Scholar
• 33. Yan P., Liu D., Long M., Ren Y., Pang J., Li R.: Changes of serumomentin levels and relationship between omentin and adiponectinconcentrations in type 2 diabetes mellitus. Exp. Clin. Endocrinol.Diabetes, 2011; 119: 257-263
  Google Scholar
• 34. Zhang J., Jin H.C., Zhu A.K., Ying R.C., Wei W., Zhang F.J.: Prognosticsignificance of plasma chemerin levels in patients with gastriccancer. Peptides, 2014; 61: 7-11
  Google Scholar
• 35. Zhang Q., Zhu L., Zheng M., Fan C., Li Y., Zhang D., He Y., YangH.: Changes of serum omentin-1 levels in normal subjects, type 2diabetes and type 2 diabetes with overweight and obesity in Chineseadults. Ann. Endocrinol., 2014; 75: 171-175
  Google Scholar
• 36. Zhang Y.Y., Zhou L.M.: Omentin-1, a new adipokine, promotesapoptosis through regulating Sirt1-dependent p53 deacetylation inhepatocellular carcinoma cells. Eur. J. Pharmacol., 2013; 698: 137-144
  Google Scholar
• 37. Zhong X., Li X., Liu F., Tan H., Shang D.: Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cellsvia ERK/NF-κB pathway. Biochem. Biophys. Res. Commun., 2012;425: 401-406
  Google Scholar

Full text